Targeted genome editing has rapidly evolved from a niche technology to a method used by many biological researchers. The widespread interest has been accelerated by the Clustered Regularly Interspaced Short
Targeted genome editing has rapidly evolved from a niche technology to a method used by many biological researchers. The widespread interest has been accelerated by the Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR) technology, which has been used to easily and efficiently modify genes in a wide variety of cell types and in organisms that have traditionally been challenging to manipulate genetically. The impact of CRISPR technology has not been fully defined, however, the power to perform targeted alterations of genome sequences could transform biological research and spur the development of novel therapeutics.
Please join us on June 29th as a distinguished panel of CRISPR experts and pioneers review the scientific and commercial opportunities and challenges of CRISPR Technology.
- Nessan Bermingham, PhD, Founder and Chief Executive Officer, Intellia Therapeutics
- Katrine Bosley, Chief Executive Officer, Editas Medicine
- Bill Lundberg, MD, Chief Scientific Officer, CRISPR Therapeutics
- George Church, PhD, Professor of Genetics, Harvard Medical School
- Chad Cowan, PhD, Associate Professor, Harvard University Department of Stem Cell and Regenerative Biology
- Erik Sontheimer, PhD, Professor of Molecular Medicine, University of Massachusetts Medical School
8:00 am – 8:30 am Registration & Networking
8:30am – 9:45am Panel #1
10:00am – 11:15am Panel #2
Please note that the objective of this event is to educate and provide information on the science and commercial potential of CRISPR and will not cover intellectual property issues.
(Monday) 8:00 am - 11:30 am